Upstream Bio, Inc. (UPB)Healthcare | Biotechnology | Waltham, United States | NasdaqGS
9.99 USD
-0.11
(-1.089%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 9.99 Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ★☆☆☆☆ |
| Model | MAE |
|---|---|
| MSTL ✓ | 1.064137 |
| AutoETS | 1.069390 |
| AutoTheta | 1.098073 |
| AutoARIMA | 1.243154 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 2.00 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 0.43 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.373 |
| Revenue per Share | 0.053 |
| Market Cap | 543,655,680 |
| Forward P/E | -3.09 |
| Website | https://upstreambio.com |
As of April 19, 2026, 6:34 p.m. EDT: Options flow is heavily skewed defensive. For the April 17 expiration, OTM Call OI is negligible compared to significant Put positioning at the 7.5 strike, which has substantial Open Interest and is the top OI strike for near-term shorts. While there is speculative Call OI built up at higher strikes (40+, 45+) for longer-dated expirations (May/Aug), the immediate specs are betting on a continuation of the downtrend. IV is wide in OTM calls for May/Aug, suggesting fear of a crash or significant upside volatility that balances the hedging demand. The mix indicates speculators are positioning for downside protection downwards of 9.99, despite the high premium cost of puts at ATM.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.02883625 |
| Address1 | 890 Winter Street |
| Address2 | Suite 200 |
| All Time High | 33.68 |
| All Time Low | 5.14 |
| Ask | 10.02 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 626,420 |
| Average Daily Volume3 Month | 1,318,411 |
| Average Volume | 1,318,411 |
| Average Volume10Days | 626,420 |
| Bid | 9.96 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 6.264 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.99 |
| Current Ratio | 26.152 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 10.62 |
| Day Low | 9.835 |
| Debt To Equity | 0.373 |
| Display Name | Upstream Bio |
| Earnings Timestamp | 1,774,528,200 |
| Earnings Timestamp End | 1,777,984,200 |
| Earnings Timestamp Start | 1,777,984,200 |
| Ebitda | -160,172,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.27 |
| Enterprise To Revenue | 71.274 |
| Enterprise Value | 203,415,664 |
| Eps Current Year | -2.93529 |
| Eps Forward | -3.2288 |
| Eps Trailing Twelve Months | -2.66 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.4886 |
| Fifty Day Average Change | -0.4986 |
| Fifty Day Average Change Percent | -0.047537327 |
| Fifty Two Week Change Percent | 2.883625 |
| Fifty Two Week High | 33.68 |
| Fifty Two Week High Change | -23.69 |
| Fifty Two Week High Change Percent | -0.7033848 |
| Fifty Two Week Low | 7.25 |
| Fifty Two Week Low Change | 2.7399998 |
| Fifty Two Week Low Change Percent | 0.377931 |
| Fifty Two Week Range | 7.25 - 33.68 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,728,653,400,000 |
| Float Shares | 34,587,711 |
| Forward Eps | -3.2288 |
| Forward P E | -3.0940287 |
| Free Cashflow | -88,750,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 75 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 2,854,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.1488 |
| Held Percent Institutions | 0.95053 |
| Implied Shares Outstanding | 54,419,987 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts. |
| Long Name | Upstream Bio, Inc. |
| Market | us_market |
| Market Cap | 543,655,680 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1773603947 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -143,443,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 543,655,660 |
| Number Of Analyst Opinions | 7 |
| Open | 10.45 |
| Operating Cashflow | -133,275,000 |
| Operating Margins | -69.11228 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 781 208 2466 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 9.99 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 10.1 |
| Price Eps Current Year | -3.4034114 |
| Price Hint | 2 |
| Price To Book | 1.5948275 |
| Price To Sales Trailing12 Months | 190.48903 |
| Profit Margins | 0.0 |
| Quick Ratio | 25.56 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.110001 |
| Regular Market Change Percent | -1.08911 |
| Regular Market Day High | 10.62 |
| Regular Market Day Low | 9.835 |
| Regular Market Day Range | 9.835 - 10.62 |
| Regular Market Open | 10.45 |
| Regular Market Previous Close | 10.1 |
| Regular Market Price | 9.99 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 645,475 |
| Return On Assets | -0.23992 |
| Return On Equity | -0.35435 |
| Revenue Growth | 0.09 |
| Revenue Per Share | 0.053 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 54,419,986 |
| Shares Percent Shares Out | 0.0631 |
| Shares Short | 3,435,261 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,086,377 |
| Short Name | Upstream Bio, Inc. |
| Short Percent Of Float | 0.11310001 |
| Short Ratio | 3.32 |
| Source Interval | 15 |
| State | MA |
| Symbol | UPB |
| Target High Price | 75.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 43.57143 |
| Target Median Price | 43.0 |
| Total Cash | 341,508,992 |
| Total Cash Per Share | 6.275 |
| Total Debt | 1,269,000 |
| Total Revenue | 2,854,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.66 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.967976 |
| Two Hundred Day Average Change | -8.977976 |
| Two Hundred Day Average Change Percent | -0.47332284 |
| Type Disp | Equity |
| Volume | 645,475 |
| Website | https://upstreambio.com |
| Zip | 2,451 |